Oxytocin Nasal Spray in the Treatment of Binge Eating Disorder and Obesity: A Pilot, Randomized, Double-Blind Trial

Roberta Agabio1,2,*, Anna Maria Giulia Farci1, Olga Curreli3, Raffaele Deidda4, Silvia Mercuro2, Romina Naitana2, Angelo Restivo2, Elisa Tronci3, Gian Luigi Gessa1,2 and Maria Rosaria Melis1,2

1Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Italy
2Center of Excellence on Neurobiology of Dependence, University of Cagliari, Italy
3Clinical Nutrition Center, Department of Medical Sciences “M. Aresu”, University of Cagliari, Italy
4Pharmaceutical Service, University of Cagliari, Italy
5Colorectal Surgery Center, Department of Surgical Sciences, University of Cagliari, Italy

Abstract

1.1. Background
Preclinical studies suggest that the neuropeptide oxytocin reduces food intake and body weight, but only a few clinical studies have investigated the translatability of these findings in humans. The present study investigated the safety and efficacy of oxytocin nasal spray in patients affected by binge eating disorder and obesity.

1.2. Methods
Seventeen outpatients affected by binge eating disorder and obesity participated in a 8 week double-blind trial and received oxytocin (n=8; 24 IU, four times a day, 20 min before each of three meals and before going to bed) or placebo (n=9) with an energy-restricted diet. Primary outcomes included adverse events and the number of binge eating episodes per week. Secondary measures included body weight, BMI, severity of BED, craving for food, quality of sleep, quality of life, anxiety, and depressive symptoms.

1.3. Results
One patient of oxytocin group discontinued prematurely the trial before the first post-randomization efficacy measure. Among the other 16 participants, 13 (81.2%) completed the trial, and 3 (18.8%) discontinued [3 in the oxytocin group; 0 in the placebo group (p=0.0625, Fisher’s exact test)]. No significant difference between groups was found in any outcome evaluated. Patients of the placebo group performed slightly better than patients of the oxytocin group in some secondary outcomes, but these differences were not significant.

1.4. Conclusion
Oxytocin nasal spray resulted to be safe, including in women of childbearing age but did not significantly reduce the number of binge eating episodes per week in outpatients affected by binge eating disorder and obesity. These findings are discussed in light of the human oxytocin literature.

Keywords: Oxytocin nasal spray; Obesity; Binge eating disorder; Body weight; Sex differences

Introduction
Binge eating disorder (BED) is a mental disorder characterized by recurrent consumption of an unusually large amount of food in a discreet period of time, accompanied by a sense of lack of control, without inappropriate compensatory behaviors typical of bulimia [1]. Consequently, BED is often associated with obesity and obese individuals with BED have a higher concern for body weight and body-shape dissatisfaction than obese individuals without BED [2]. BED is also associated with significant psychiatric comorbidities, such as mood and anxiety disorders [1].

Pharmacologic agents (antidepressants, anticonvulsants, and obesity drugs) have shown moderate effectiveness for the treatment of BED and the only medication approved in the US, but not in Europe, is a prodrug of dextroamphetamine, lisdexamfetamina dimesylate [3].

In the last 20 years, knowledge regarding the central and peripheral mechanisms controlling food intake, energy balance, metabolism, and related aspects, such as appetite and satiety, has greatly increased and numerous neurotransmitters, neuropeptides, and hormones involved in these mechanisms have been identified [4]. Interestingly, a large body of findings supports a prominent role for oxytocin in the modulation of food intake and body weight in animal models [5].

Oxytocin is a neuropeptide primarily produced in the supraoptic (SON) and paraventricular (PVN) hypothalamic nuclei and released by the neurohypophysis into the bloodstream for its hormonal effects in lactation and uterine contractions [6]. Hypothalamic oxytocinergic neurons also project to specific central areas involved in the modulation of motivation, sense of well-being, and sexual performance [6,7]. A large number of studies found that administration of oxytocin reduces food intake and body weight in animal models of obesity [5,8].

Only a few studies have investigated the role of oxytocin in human nutrition [9-12]. In the first study, intravenous administration of oxytocin to healthy subjects reduced, instead of increasing, the sensation

*Corresponding author: Roberta Agabio, Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cittadella Universitaria, Monserrato (CA), Italy, Tel: +39 070 6754325; E-mail: agabio@unica.it

Received March 16, 2016; Accepted April 06, 2016; Published April 12, 2016


Copyright: © 2016 Agabio R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
of satiety [9]. More recent trials used the new intranasal formulation of oxytocin [13]. This route of administration allows oxytocin to penetrate into the central nervous system, likely through olfactory epithelial intercellular spaces [13]. In one study, the administration of this formulation (24 IU) to individuals of normal weight reduced the consumption of palatable food but not hunger-driven eating [10]. In another study, the administration of oxytocin nasal spray (24 IU) to obese patients, four times a day, approximately 20 min before meals and sleep for 8 weeks effectively reduced body weight [11]. In the last study, the administration of oxytocin nasal spray (24 IU) to fasting healthy subjects, 60 min before meal, reduced caloric intake with a preferential effect on fat intake without affecting appetite [12].

Oxytocin increases the ability to identify emotions and the empathy towards others [14] and may have therapeutic potential for psychiatric illnesses that impact social functioning, such as autism, schizophrenia, anxiety, and depression [15,16].

Some features of BED are similar to those of Substance Use Disorders (SUDs) [1]. For example, the urge to consume food and the sense of lack of control in BED patients are similar to the urge to consume alcohol or other substances of abuse (craving) and the sense of lack of control in SUD patients. BED and SUDs also share similar neural substrates [17]. The consumption of food (particularly foods rich in carbohydrates and fats), as well as the consumption of substances of abuse, induce rewarding effects, at least in part, through activation of the mesolimbic dopaminergic “reward” system that in vulnerable individuals may induce the development of BED and SUDs, respectively [17]. The interactions of central oxytocinergic neurons with the “reward” system are well documented [18]. In animal models, the administration of oxytocin attenuates several behaviors related to different substances of abuse (heroin, alcohol, cocaine, and psychostimulants) [19,20]. Conversely, the role of oxytocin in the treatment of SUDs in humans is unclear as only a few clinical studies [21,22] investigated its effects with contrasting results.

Oxytocin nasal spray may have a role in the treatment of patients affected by BED and obesity (BED+O), but no study has been conducted to date to investigate its safety and efficacy in these patients.

Materials and Methods

Participants

Study participants were recruited at the Clinical Nutrition Unit of the University Hospital of Cagliari. Patients were eligible for the study if they met DSM-5 criteria for BED and had a body mass index (BMI; body weight in kg divided by height in m^2) ≥ 30 kg/m^2. Other inclusion criteria were: (1) 21-65 years of age; (2) residence in a location that allowed the patient to comply with the scheduled visits; (3) the ability to understand the aims of the study, agree to participate in the study, and sign the informed consent form. The exclusion criteria were: (1) 21-65 years of age; (2) current physical diseases (cancer, hypertension, heart disease, and cirrhosis) or psychiatric disorders (psychotic and personality disorders) that, in the physician’s opinion, may constitute a danger for participation in the study; (3) start of any pharmacologic treatment within the past 2 months; (4) use of psychotherapy and/or pharmacotherapy for BED; (5) abnormal liver and/or kidney function; (6) for women of childbearing age, to be pregnant, lactating, or not practicing a form of medically accepted contraception. The Institutional Review Board at the University of Cagliari approved the study protocol (EudraCT number: 2014-002983-33; authorization no. 12888, 23 July 2014). The study was conducted in compliance with the Declaration of Helsinki. All patients signed approved written informed consent forms. Patients were enrolled from December 2014 through April 2015.

Study Design

The study was a pilot 8 week, outpatient, randomized, double-blind trial. The trial consisted of the following phases: (1) a 2 week screening period; (2) a 8 week double-blind treatment period; and (3) a 1 week treatment discontinuation period. Patients were evaluated twice during the screening period, three times during the pharmacologic treatment (after 1, 4 and 8 weeks), and once one week after medication discontinuation.

During the screening period, patients were interviewed to collect demographic and clinical information and submitted to a physical examination during which vital signs, height, and weight were measured and the BMI was calculated. Then, blood chemical and hematologic tests were requested. Women of childbearing age were given a urine pregnancy test. Only patients with normal blood chemical and hematologic tests and negative pregnancy tests were eligible for the psychiatric visit. One week later, patients were submitted to the psychiatric visit during which the diagnosis of BED and co-morbid mental disorders were investigated using the Structured Clinical Interview for DSM-IV, Axis I Disorders (SCID-I). Patients who satisfied the inclusion and exclusion criteria were asked to take part in the study, and to sign the written informed consent forms. Then, BED+O patients who accepted and signed the consent forms were randomized to receive oxytocin or placebo according to computer-generated coding. Allocation concealment was achieved by having the research pharmacy perform the randomization, package the study medication, and maintain the integrity of the blinded information throughout the trial, including the statistical evaluation of the results. One week after medication discontinuation, patients were submitted to a visit aimed at investigating possible disorders due to discontinuation.

Medications

Medications were supplied by Defiate/Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. in packs containing 40 IU of oxytocin per ml or placebo. The composition of oxytocin and placebo nasal sprays was identical, except for the hormone. Medication kits were marked with progressive numbers by the research pharmacy. Each kit contained a sealed envelope, marked by the same number of the kit, which contained the contents of the packs (oxytocin or placebo). The opening would have allowed the investigators to discover the contents of the medication spray if necessary without affecting the double-blind trial of the other patients. Drugs were kept by the research pharmacy at 4°C until given to patients.

At the end of the first psychiatric visit, patients received medications and recommendations for their nasal administration [13]. Doses of placebo and oxytocin were equal to 6 puffs (24 IU), four times a day, 20 min before each of three meals and before going to bed (96 IU per day).

After the first week of treatment, the appearance of possible acute side effects was evaluated.

Diet

Participants received a balanced, energy-restricted (-200 kcal/day of resting energy expenditure) diet (% carbohydrate:fat:protein= ~ 55:25:20) containing a specific list of appropriate foods compatible with their individual preferences.

Outcome measures

The primary outcomes were the appearance of adverse effects and the number of binge eating episodes per week self-registered in diaries by participants and confirmed on clinical interview. The diaries were provided to participants at the screening evaluation. Participants
were instructed to monitor and record into the diary the binge eating episodes, including a detailed description of the type of food consumed, the duration of each episode as well as the possible adverse effects. Binge eating episodes were defined using DSM-5 criteria. At each visit, the diaries were reviewed with participants. Information on menstrual cycles and possible uterine side effects were requested to female participants of childbearing age.

Secondary efficacy measures included body weight (BW), BMI, and scores achieved on scales used to investigate the severity of BED, craving for food, quality of sleep, quality of life, anxiety, and depressive symptoms. The severity of BED was evaluated using the Clinical Global Impression-Severity scale (CGI-S) according to the physician’s opinion [23] and the Binge Eating Scale (BES) according to the participant’s opinion [24]. The severity of craving for food and quality of life were evaluated using visual analogue scales, asking patients to indicate a score from 0-100 mm. Quality of life was evaluated using the Short-Form Health Survey (SF-12) [25]. Severity of anxiety symptoms was evaluated using the Spielberger State Anxiety Inventory (STAI) and severity of depressive symptoms using the Zung Self Rating Depression Scale (ZUNG) [26]. Compliance was evaluated by counting the returned bottles. At each visit, patients were assessed for adverse events, number of binge episodes per week, BW, BMI, vital signs, medication compliance, and scores on the CGI-S, BES, SF-12, STAI, VAS, and ZUNG.

**Statistical analysis**

Data were analyzed using IBM SPSS Statistics software (version 21.0).

We performed an efficacy analysis by comparing changes between groups in the outcome variables during the treatment period. The analysis assessed the change of the mean of each variable measured at each visit during the treatment period (number of binge episodes per week, BW, BMI, scores obtained in the CGI-S, BES, SF-12, STAI, VAS, and ZUNG). To explore statistical significance, we performed a longitudinal repeated-measures random regression analysis with a model that included terms for treatment, time, and treatment-by-time interaction [27]. Time was modeled as a continuous variable, with weeks ranging from 0 (baseline) to 8, after beginning treatment with oxytocin or placebo. For the analyses of binge frequency the logarithmic transformation log (binge days/week) + 1) was used to normalize the data and stabilize the variance. The measure of effect was normalized by using a mixed effect model with maximum likelihood estimation. Heterogeneous first-order autoregressive covariance structure for repeated and random effect was used, as this resulted the best fitting model with the lowest standard error of the estimates.

The analysis was intent-to-treat (ITT), using available observations on all participants who completed a baseline evaluation. Data of all randomized participants who took at least 1 puff and completed at least 1 safety assessment were included in the safety analysis. Data of all participants who took at least 1 puff of the medications under study and had at least 1 post baseline efficacy assessment were included in the efficacy analysis.

The baseline characteristics of each group were compared by using chi-square or Fisher’s exact test for categorical variables and independent-samples t tests for continuous variables. A two sided p value 0.05 was considered significant.

**Results**

Of the 69 individuals screened, 52 were not enrolled because they did not meet entry criteria (N=17), chose not to participate (N=15), had a physical disease (hypertension) that contraindicated participation in the study (N=16), started a new pharmacotherapy within the past 2 months (N=1), or were lost to follow-up after the screening visit (N=3). Seventeen BED+O patients met the entry criteria and were randomized to oxytocin (N=8) or placebo (N=9). Sixteen participants (94%) were women; 8 were of childbearing age (4 in the oxytocin group and 4 in the placebo group) and 8 were post-menopausal or pre-menopausal (3 in the oxytocin group and 5 in the placebo group). Three patients (17.6%) had mood or anxiety disorders. There were no significant differences between the treatment groups at baseline (Table 1).

<table>
<thead>
<tr>
<th></th>
<th>Oxytocin (n=8)</th>
<th>Placebo (n=9)</th>
<th>p value a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, n (%)</td>
<td>7 (87.5)</td>
<td>9 (100.0)</td>
<td>0.4706</td>
</tr>
<tr>
<td>Mean age in years (SD)</td>
<td>47.5 (4.5)</td>
<td>49.8 (10.2)</td>
<td>0.5685</td>
</tr>
<tr>
<td>Actual mood disorders, n (%)</td>
<td>1 (12.5)</td>
<td>1 (11.1)</td>
<td>1.0000</td>
</tr>
<tr>
<td>Actual anxiety disorders, n (%)</td>
<td>0 (0.0)</td>
<td>1 (11.1)</td>
<td>1.0000</td>
</tr>
<tr>
<td>BW (SD)</td>
<td>49.3 (3.3)</td>
<td>60.0 (2.7)</td>
<td>0.4535</td>
</tr>
<tr>
<td>BW (SD)</td>
<td>90.8 (23.4)</td>
<td>95.3 (17.2)</td>
<td>0.6554</td>
</tr>
<tr>
<td>BMI (SD)</td>
<td>24.1 (5.7)</td>
<td>37.6 (5.2)</td>
<td>0.1408</td>
</tr>
<tr>
<td>BE (SD)</td>
<td>45.9 (1.0)</td>
<td>49.0 (1.1)</td>
<td>0.0862</td>
</tr>
<tr>
<td>Quality of sleep (SD)</td>
<td>75.3 (27.0)</td>
<td>59.7 (36.3)</td>
<td>0.3370</td>
</tr>
<tr>
<td>SF-12 (SD)</td>
<td>31.5 (6.9)</td>
<td>28.1 (7.2)</td>
<td>0.3399</td>
</tr>
<tr>
<td>STAI (SD)</td>
<td>48.5 (13.2)</td>
<td>53.0 (14.0)</td>
<td>0.5076</td>
</tr>
<tr>
<td>VAS (SD)</td>
<td>80.3 (16.6)</td>
<td>81.1 (15.4)</td>
<td>0.9193</td>
</tr>
<tr>
<td>ZUNG (SD)</td>
<td>41.3 (11.5)</td>
<td>41.3 (12.2)</td>
<td>0.9887</td>
</tr>
<tr>
<td>ALT (SD)</td>
<td>37.2 (29.6)</td>
<td>24.2 (11.3)</td>
<td>0.2385</td>
</tr>
<tr>
<td>AST (SD)</td>
<td>21.3 (8.2)</td>
<td>22.8 (9.7)</td>
<td>0.7336</td>
</tr>
<tr>
<td>Creatinine (SD)</td>
<td>0.8 (0.1)</td>
<td>0.7 (0.2)</td>
<td>0.2531</td>
</tr>
<tr>
<td>Urea (SD)</td>
<td>33.0 (9.3)</td>
<td>34.8 (11.0)</td>
<td>0.7620</td>
</tr>
<tr>
<td>Cholesterol (SD)</td>
<td>209.3 (25.4)</td>
<td>209.4 (28.0)</td>
<td>0.9883</td>
</tr>
<tr>
<td>HDL Cholesterol (SD)</td>
<td>56.4 (9.8)</td>
<td>58.6 (8.1)</td>
<td>0.6242</td>
</tr>
<tr>
<td>LDL Cholesterol (SD)</td>
<td>124.8 (31.8)</td>
<td>135.7 (17.1)</td>
<td>0.4089</td>
</tr>
<tr>
<td>Triglycerides (SD)</td>
<td>137.3 (67.7)</td>
<td>107.6 (47.3)</td>
<td>0.3063</td>
</tr>
</tbody>
</table>

*Chi-square, Fisher’s exact test or t-tests were used to determine statistical differences between the oxytocin and placebo groups.

Table 1: Baseline characteristics of obese participants with binge eating disorder randomly assigned to 8 weeks of double-blind treatment with oxytocin or placebo.

ALT: Serum Aspartate Transaminase Levels
AST: Serum Asparate Transaminase Levels
BE: Number of episodes of binge eating per week
BES: Binge Eating Scale Score [a 16-item scale used to assess the severity of binge eating behavior with a total score varying from 0 to 46; (non-binging ≤ 17; moderate binging=18-27; severe binging ≥ 27)]
BMI: Body Mass Index (weight in kilograms divided by height in m², normal value=25)
CGI-S: Clinical Global Impression-S, rating scale for clinical global impression of severity of binge eating disorder (BED) [total score varies from 1 (no BED) to 7 (the most severe BED)]
CGI-S: Clinical Global Impression-Severity scale (CGI-S) according to the physician’s opinion [23]
CGI-S: Clinical Global Impression-S, rating scale for clinical global impression of severity of binge eating disorder (BED) [total score varies from 1 (no BED) to 7 (the most severe BED)]
HDLC: High-Density Lipoprotein Cholesterol (recommended ranges >60 mg/dl)
LDLC: Low-Density Lipoprotein Cholesterol (recommended ranges <100 mg/dl)
Quality of sleep: Score achieved on a visual analog 100 mm scale (0=worst quality of sleep and 100 mm=the best quality of sleep)
SD: Standard Deviation
STAI: State Anxiety Inventory Scale used to measure the severity of anxiety symptoms (total score varies from 40 to 80; scores ≥40 are indicative of significant anxiety)
VAS: Visual Analogue Scale of food craving (0=no craving and 100 mm=the worst craving)
ZUNG: Zung Self Rating Depression Scale (ZUNG) [a 16-item scale used to assess the severity of binge eating behavior with a total score varying from 0 to 46; (non-binging ≤ 17; moderate binging=18-27; severe binging ≥ 27)]
The observed mean outcome measures at week 8 (for the 13 completers) along with the analysis of change in outcome measures are presented in Tables 3 and 4. Both the longitudinal and end point analyses revealed no statistically significant differences between groups in the changes in any of the outcomes evaluated. A tendency to different effects between the two groups was found for some outcomes (BMI, CGI, and STAI scores) with patients of the placebo group showing a better result. However, this difference was not significant.

The observed mean outcome measures at week 8 (for the 13 completers) along with the analysis of change in outcome measures are presented in Tables 3 and 4. Both the longitudinal and end point analyses revealed no statistically significant differences between groups in the changes in any of the outcomes evaluated. A tendency to different effects between the two groups was found for some outcomes (BMI, CGI, and STAI scores) with patients of the placebo group showing a better result. However, this difference was not significant.

**Discussion**

As far as our best knowledge, this is the first study to evaluate the efficacy and safety of oxytocin nasal spray in BED and obese patients. No difference was found between oxytocin and placebo in the number of episodes of binge eating, body weight, severity of craving for food, and severity of binge eating disorder (BED) [total score varies from 1 (no BED) to 7 (the most severe BED)].

<table>
<thead>
<tr>
<th>Event, n (%)</th>
<th>Oxytocin (n=8)</th>
<th>Placebo (n=9)</th>
<th>Fisher’s exact test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bed/week (Log10)</td>
<td>Mean W0</td>
<td>Difference</td>
<td>Mean W0</td>
</tr>
<tr>
<td>VAS</td>
<td>611.11 (4.954)</td>
<td>-4.667 (7.685)</td>
<td>80.313 (5.254)</td>
</tr>
<tr>
<td>Difference in variation</td>
<td>4.119 (12.216)</td>
<td>0.758</td>
<td></td>
</tr>
<tr>
<td>BES</td>
<td>23.333 (2.313)</td>
<td>-12.222 (3.473)</td>
<td>21.625 (2.454)</td>
</tr>
<tr>
<td>Difference in variation</td>
<td>6.195 (5.889)</td>
<td>0.305</td>
<td></td>
</tr>
<tr>
<td>CGI</td>
<td>4.889 (0.314)</td>
<td>-2.444 (0.628)</td>
<td>4.000 (0.333)</td>
</tr>
<tr>
<td>Difference in variation</td>
<td>1.949 (1.082)</td>
<td>0.088</td>
<td></td>
</tr>
<tr>
<td>SF-12</td>
<td>0.689 (0.215)</td>
<td>0.158 (0.322)</td>
<td>0.633</td>
</tr>
<tr>
<td>Difference in variation</td>
<td>0.158 (0.322)</td>
<td>0.633</td>
<td></td>
</tr>
<tr>
<td>ZUNG</td>
<td>0.744 (0.080)</td>
<td>0.158 (0.322)</td>
<td>0.633</td>
</tr>
<tr>
<td>Difference in variation</td>
<td>0.158 (0.322)</td>
<td>0.633</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2**: Adverse events reported by obese participants with binge eating disorder receiving treatment with oxytocin or placebo.

<table>
<thead>
<tr>
<th>Event, n (%)</th>
<th>Oxytocin (n=8)</th>
<th>Placebo (n=9)</th>
<th>Fisher’s exact test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any</td>
<td>6 (75.0)</td>
<td>6 (66.7)</td>
<td>p=1.0000</td>
</tr>
<tr>
<td>Sleepness</td>
<td>1 (12.5)</td>
<td>2 (22.2)</td>
<td>p=1.0000</td>
</tr>
<tr>
<td>Headache</td>
<td>1 (12.5)</td>
<td>2 (22.2)</td>
<td>p=1.0000</td>
</tr>
<tr>
<td>Uterine pain during menstrual cycle</td>
<td>0 (0.0)</td>
<td>1 (11.1)</td>
<td>p=1.0000</td>
</tr>
<tr>
<td>Nausea</td>
<td>0 (0.0)</td>
<td>1 (11.1)</td>
<td>p=1.0000</td>
</tr>
<tr>
<td>Erythema</td>
<td>1 (12.5)</td>
<td>3 (33.3)</td>
<td>p=0.5765</td>
</tr>
<tr>
<td>Dizziness</td>
<td>0 (0.0)</td>
<td>1 (11.1)</td>
<td>p=1.0000</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>1 (12.5)</td>
<td>1 (11.1)</td>
<td>p=1.0000</td>
</tr>
<tr>
<td>Palpitations</td>
<td>2 (25.0)</td>
<td>1 (11.1)</td>
<td>p=0.5765</td>
</tr>
</tbody>
</table>

* This patient discontinued the trial due to erythema.

**Table 3**: Analysis of change in outcome measures.

BE: Number of episodes of binge eating per week

Binge Eating Scale score (a 16 item scale used to assess the severity of binge eating behavior with a total score varying from 0 to 46 (non-bingeing ≤ 17; moderate binging=18-26; severe binging ≥ 27)

BMI: Body Mass Index (weight in kilograms divided by height in m², normal value<25)

CGI-S: Clinical Global Impression-S, rating scale for clinical global impression of severity of binge eating disorder (BED) [total score varies from 1 (no BED) to 7 (the most severe BED)]

Quality of sleep, score achieved in a visual analog 100 mm scale (0=the worst quality of sleep; 100=the best quality of sleep)

SF-12: Score achieved on a 12-item questionnaire used to measure the quality of life [total score varies from 12 to 47 (12=the worst quality of life; 47=the best quality of life)]

STAI: Score achieved on the Spielberger State Anxiety Inventory scale used to measure the severity of anxiety symptoms (total score varies from 0 to 100; scores ≥40 are indicative of significant anxiety)

VAS: Score achieved on a Visual Analogue Scale of food craving (0=no craving; 100 mm=the worst craving)

ZUNG: Score achieved on a 20-item scale used to assess the severity of depressive symptoms (total score varies from 20 to 80; scores ≥ 50 are indicative of significant depression)
BE: Number of episodes of binge eating per week
BES: Binge Eating Scale score [a 16 item scale used to assess the severity of binge eating behavior with a total score varying from 0 to 46 (non-binging≤17; moderate binging=18-26; severe binging ≥ 27)]
BMI: Body Mass Index (weight in kilograms divided by height in m²; normal value<25);
BW: Body Weight (in kilograms)
CGI-S: Clinical Global Impression-S, rating scale for clinical global impression of severity of binge eating disorder (BED) [total score varies from 1 (no BED) to 7 (the most severe BED)]
Quality of sleep, score achieved on a visual analog 100 mm scale (0=the worst quality of sleep; 100=the best quality of sleep)
SF-12: Score achieved on a 12-item questionnaire used to measure the quality of life [total score varies from 12 to 47 (12=the worst quality of life; 47=the best quality of life)]
STAI: Score achieved in the Spielberger State Anxiety Inventory scale used to measure the severity of anxiety symptoms (total score varies from 40 to 80; scores ≥40 are indicative of significant anxiety)
VAS: Score achieved on a Visual Analogue Scale of food craving (0=no craving; 100 mm=the worst craving)
ZUNG mean (SD) 42.3 (12.0) 41.3 (12.2) 43.6 (10.3) 43.6 (20.2) 39.5 (7.9) 43.6 (20.2)

<table>
<thead>
<tr>
<th>W0 (n=16)</th>
<th>Last Observation * (n=16)</th>
<th>WB b (n=13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytocin (n=7)</td>
<td>Placebo (n=9)</td>
<td>Oxytocin (n=7)</td>
</tr>
<tr>
<td>BE mean (SD)</td>
<td>5.1 (3.6) 6.0 (2.7)</td>
<td>4.0 (4.6) 2.4 (3.2)</td>
</tr>
<tr>
<td>BW mean (SD)</td>
<td>92.5 (24.7) 95.3 (17.2)</td>
<td>91.4 (24.9) 92.7 (18.8)</td>
</tr>
<tr>
<td>BMI mean (SD)</td>
<td>34.7 (3.5) 37.6 (5.2)</td>
<td>34.4 (3.7) 36.5 (6.2)</td>
</tr>
<tr>
<td>BES mean (SD)</td>
<td>21.4 (8.1) 23.7 (7.2)</td>
<td>15.4 (7.3) 11.1 (10.1)</td>
</tr>
<tr>
<td>CGI-S mean (SD)</td>
<td>4.0 (1.0) 4.8 (1.1)</td>
<td>3.1 (1.3) 2.4 (1.9)</td>
</tr>
<tr>
<td>Quality of sleep mean (SD)</td>
<td>74.6 (29.1) 59.7 (36.3)</td>
<td>75.7 (31.0) 86.7 (21.2)</td>
</tr>
<tr>
<td>SF-12 mean (SD)</td>
<td>31.9 (7.4) 28.1 (7.2)</td>
<td>31.6 (8.9) 32.9 (7.0)</td>
</tr>
<tr>
<td>STAI mean (SD)</td>
<td>45.9 (11.8) 53.0 (14.0)</td>
<td>50.1 (12.5) 43.6 (18.3)</td>
</tr>
<tr>
<td>VAS mean (SD)</td>
<td>84.6 (12.1) 81.1 (15.4)</td>
<td>40.7 (24.4) 34.4 (20.2)</td>
</tr>
</tbody>
</table>

**Table 4:** Efficacy measures.

effects. A higher rate of patients of oxytocin group reported an episode of palpitations. However, this difference did not achieve a statistical significance.

Several factors may have contributed to the lack of efficacy observed in the present study. Preclinical studies indicate that oxytocin administration decreases food consumption and body weight in obese and lean animals [5] but the few clinical studies conducted to date have produced conflicting results [9-12].

Only one of these studies evaluated the efficacy of oxytocin nasal spray in obese subjects finding that it significantly decreased the body weight [11]. Despite we used the same schedule of administration and dose of this study, in our study oxytocin nasal spray failed to reduce body weight. Some methodological differences between the two studies may at least in part explain this discrepancy. First, the presence of a mental disorder (e.g. BED) was an exclusion criterion in the study by Zhang et al. [11] and an inclusion criterion in our study. It has been found that the presence of binge eating behavior predicted worse weight outcomes in overweight/obese veterans enrolled in weight loss treatment [28]. Namely, subjects without binge eating lost almost twice as much weight compared to those with binge eating, and high-frequency binge eating was associated with weight gain. It is possible that in our study, the lack of efficacy of oxytocin may be due to the presence of BED. Accordingly, BED+O patients may require higher doses of oxytocin to reduce body weight than those required by obese subjects without BED.

Another difference between the two studies consists in the energy-restricted diet that participants received in our study, while in the study conducted by Zhang et al. [11], participants did not receive an energy-restricted diet. It has been observed that oxytocin reduced the intake of palatable foods, but was not able to modify food intake in the fasted state [10]. Accordingly, the lack of efficacy in reducing food intake observed in our study may be due to the energy-restricted diet received by participants. It is possible that to reveal possible anorexic effects of oxytocin in BED+O patients, subjects should receive a free diet.

The high response to placebo of BED patients [29] may have also contributed to conceal the response to oxytocin. The effects induced by oxytocin may vary in individuals affected by different eating disorders. For example, a dysregulation of oxytocin secretion has been found in anorexic women but not in bulimic women [30,31]. Another study found that the administration of oxytocin nasal spray (40 IU) reduced food consumption in bulimic women but not in anorexic women [32].

The response to oxytocin may also vary according to the schedule of administration. In our study, a fixed schedule was used (20 min before meals and before going to bed) even if two patients asked to modify it into a flexible schedule, “as needed treatment”. Interestingly, in humans, increased salivary oxytocin levels last for less than 2 h after the administration of oxytocin nasal spray (24 IU, the same dose used in our study) [33]. It may be possible that the fixed schedule of oxytocin administration could reduce food craving during this 2 h period but not after. Further clinical trials should be conducted to investigate the potential efficacy of oxytocin for the treatment of BED using flexible schedules, according to the need of patients.

Preclinical studies suggest a possible role of oxytocin in the treatment of SUDs [19,20]. Considering the analogies between SUDs and BED, we hypothesized that the administration of oxytocin nasal spray may be able to reduce the severity of craving for food in BED+O subjects. However, in our study, oxytocin did not reduce the severity of food craving in BED+O subjects. Another study recently failed to demonstrate positive effects of oxytocin nasal spray in SUD patients [21]. In details, a single administration of oxytocin nasal spray (24 IU) increased the severity of craving for cocaine (instead of reducing it) in cocaine-dependent patients.
Another study showed that oxytocin nasal spray did not induce beneficial effects in individuals with Prader-Willi syndrome (PWS) [34]. This genetic syndrome is characterized by complex physical, behavioral, and intellectual abnormalities, and hyperphagia [35]. If food consumption is left unmanaged, individuals with PWS develop obesity. It has been hypothesized that hyperphagia might be due to oxytocin deficiency found in PVN of patients affected by PWS [34]. Accordingly, it has been hypothesized that oxytocin nasal spray may reduce food consumption and body weight in patients affected by PWS. Conversely, its administration (36-80 IU daily, divided into two daily administrations) did not reduce food consumption and body weight in these individuals [34].

Other studies reported unattended results [36-38]. For instance, oxytocin nasal spray resulted to be anxiogenic instead of anxiolytic in depressed patients [36], increased the perception of social stress instead of decreased it [37], and did not reduce anxiety and depressive symptoms in fibromyalgic patients [38]. It has been proposed that the effects induced by oxytocin may also vary according to the social or behavioral context [39].

Another factor that may have contributed to the unattended results found in the present study may be due to the large number of female participants recruited. Recent studies have suggested that the response to oxytocin nasal spray may differ between male and female participants. A recent meta-analysis of imaging studies found that in certain brain regions, oxytocin nasal spray induces almost opposite effects in men and women during the processing of different tasks [40].

The majority of preclinical studies conducted to investigate the efficacy of oxytocin in reducing food intake and body weight used mostly male animals [8]. Also clinical studies conducted to investigate the efficacy of oxytocin nasal spray in nutrition recruited mainly male participants [9-12]. Interestingly, the only male participant (who also received oxytocin) recruited by the current study had a positive response to medical treatment. Another study found that the daily administration of oxytocin nasal spray (40 IU) for four months did not modify BMI of 32 schizophrenic patients, mainly constituted by male participants (27 men and 5 women) [41]. Globally, these data suggest that further studies aimed at investigating the effects of oxytocin nasal spray in reducing food consumption and/or body weight should evaluate possible sex differences to these effects. But only recently, possible sex differences in the response to oxytocin as well as among BED patients are under investigation [42-44].

This study has several limitations, one being the small number of subjects recruited. This number was in part justified by the need to investigate the safety of oxytocin in a population of patients at high risk of possible complications, such as BED+O patients. One patient of oxytocin group discontinued the trial after 1 week of treatment due to erythema, but other three patients of the placebo group developed the same side effect although they did not discontinue the trial. Accordingly, this side effect does not seem to be related to the presence of oxytocin in the nasal spray formulation. In addition, no participant required higher doses of oxytocin during the study, suggesting the lack of craving for this medication. Oxytocin nasal spray resulted to be devoid of uterine side effects in female participants of childbearing age. Furthermore, no side effect was observed at the end of the pharmacological treatment (one week after treatment discontinuation), suggesting that the interruption of an 8 week oxytocin treatment did not induce health problems in the sample of BED+O patients who completed the study.

In conclusion, despite the rationale for evaluating the effects in BED+O patients, the present study showed that a 8 week treatment with oxytocin nasal spray did not reduce craving for food and body weight but resulted to be safe in this sample of patients, the majority of whom were women. Possible reasons for the lack of efficacy of oxytocin nasal spray include the almost exclusively presence of female participants, the energy-restricted diet, the dose, and the fixed schedule of administration. Globally, these results suggest that future studies aimed at investigating the efficacy of oxytocin nasal spray in obese patients with BED should recruit adequate number of female and male participants to investigate possible gender differences, permit a free diet, and administer higher doses of oxytocin, in a flexible schedule.

Acknowledgement

The authors express gratitude to Defiante/Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. for supplying oxytocin and placebo nasal spray.

The authors express also sincere gratitude to Alessandra Chessa, Clinical Nutrition Center, Department of Medical Sciences “M. Aresu”, University of Cagliari, Italy for her contribution and to David Cushey for language editing of the manuscript.

Conflict of Interest

The authors have no financial or non-financial conflict of interest to declare.

References


